Keeping Track Of New Drugs: US FDA Review Queue Adds Spark Gene Therapy, Amgen Migraine Antibody, Bayer Oncologic
The latest news about novel agent applications from our FDA Performance Tracker.
You may also be interested in...
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
News and highlights about novel agents from our FDA Performance Tracker.
Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins
Lilly will seek FDA approval in the second half of 2017 for CGRP inhibitor galcanezumab based on three positive Phase III studies – within months of a filing for Amgen's and Novartis's CGRP inhibitor erenumab.